- Home
- ESS vs NBIX Comparison
ESS vs NBIX Comparison
Compare ESS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESS | NBIX |
|---|---|---|
| Founded | 1971 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 15.5B |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ESS | NBIX |
|---|---|---|
| Price | $288.37 | $152.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 22 |
| Target Price | ★ $279.90 | $180.91 |
| AVG Volume (30 Days) | 376.4K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 2.62 | ★ 3.30 |
| Revenue | ★ $1,887,345,000.00 | $161,626,000.00 |
| Revenue This Year | $1.84 | $24.73 |
| Revenue Next Year | $3.35 | $13.14 |
| P/E Ratio | $109.81 | ★ $46.34 |
| Revenue Growth | 6.36 | ★ 977.51 |
| 52 Week Low | $238.46 | $122.14 |
| 52 Week High | $303.35 | $186.12 |
Technical Indicators
Market Signals| Indicator | ESS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 37.25 |
| Support Level | $248.62 | $152.67 |
| Resistance Level | $288.31 | $161.29 |
| Average True Range (ATR) | 5.04 | 4.10 |
| MACD | 0.22 | -1.08 |
| Stochastic Oscillator | 54.57 | 21.47 |
Price Performance
Historical ComparisonAbout ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 259 apartment communities with over 63,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.